TIKUN Europe, the first pharmaceutical company active in the field of medical cannabis in Greece, has completed the construction of its greenhouse cultivation unit, which is located at the region of Corinth, in Peloponnese. The company will apply for the operations license by the end of March 2022. With an investment that is expected to exceed €40.000.000, TIKUN Europe has created a 56,000m2 state-of-the-art production site, with facilities and equipment of latest technology. The facility has three distinct units: the greenhouse cultivation area, the post-harvest processing area and the area designated for the production and packaging of finished medical cannabis products.
The 21,000m2 greenhouse is the first unit designed to produce medical cannabis in Greece and the site where actual cultivation of medical cannabis plants will take place in the upcoming months. The plants will be used to create TIKUN Europe’s innovative and high-quality medical cannabis products. The facility has an annual production capacity of 10tons of dry flower that can be used for the production of various finished dosage forms. Plans include its possible expansion by 50%, with a subsequent production increase.
Overall, TIKUN Europe’s greenhouse and manufacturing facility complies with EU GACP/GMP standards and local legislation for the cultivation and processing of medical cannabis.
All process steps are incorporated in the Quality System of the company, ensuring the high product quality and safety.
The company is in the process of obtaining all the necessary licenses and certifications and will operate with high responsibility and respect to the environment and the local community.
The cultivation operations are estimated to commence in April 2022. The GMP certification and the initiation of operations of the manufacturing facility is scheduled for June 2022.
TIKUN Europe is about to launch a complete range of CBD products; the TIKUN CBD range, a Holistic, Natural Balance offering, which is produced in a certified Factory in France.
TIKUN is a pioneering company in the research, development, and production of medicinal cannabis products worldwide. Defining the market of medicinal cannabis in 2005, it began its activity in Israel and in the course of time expanded with production units in the USA, Canada, Australia, Asia (Israel) and Europe (based in Greece). With more than 15 years of clinical and laboratory studies and an extensive database of tens of thousands of patients worldwide, TIKUN's innovative pharmaceutical formulations are based on cannabis strains that have been awarded worldwide. Its medications offer support for serious conditions, such as Parkinson's disease, Crohn's disease, Autism, multiple sclerosis, epilepsy, side effects from chemotherapy, neuropathic pain, etc.
About TIKUN Europe
TIKUN Olam Europe's presence in Europe began in Greece, taking advantage of the country's potential to develop into an international center for the production of medicinal cannabis, with most of the production aimed for exportation to European countries.
With a total investment of €40m, in a 56,000m2 area in Corinth, TIKUN Europe has created the largest, for this sector, production unit in Europe, with a vertically integrated production process and an R&D department, in state-of-the-art facilities and with equipment of latest technology.
TIKUN Europe’s activity is fully aligned with the GACP/GMP principles and the provisions of Greek legislation for the cultivation and processing of medical cannabis, ensuring high product quality and safety.
The company utilizes TIKUN’s know-how, while having direct access to its large patient database. TIKUN's pharmaceutical formulations have effectiveness which has been verified following clinical studies and Real-World Data (RWD).
At the beginning of 2022, TIKUN Europe will launch its CBD product line, which is produced in a certified factory in France, based on innovative formulas developed by its R&D division. The TIKUN CBD series helps with the everyday life annoyances, while at the same time benefits the entire human body. In other words, it ensures homeostasis, providing holistic, natural balance.
V+O Communication, Nasia Bourni - Tel. Contact 210 72 49 000 / 6936775484 - Email firstname.lastname@example.org